Current Issue

View Larger Image

Past Issues Free Subscriptions
Sponsored
Keywords



Search Results - Vical
 More »

  • Vical Scraps Melanoma Candidate After Phase III Failure
    Vical said today it would end development of its lead drug Allovectin® (velimogene ... Vical said that it would refocus its development efforts on vaccines for infectious ...
    8-12-2013
  • People in the News
    Reynders has held senior leadership positions at Johnson & Johnson, Lilly, and Celera Genomics. Vical appointed Richard M. Beleson and Stephen A. Sherwin, M.D. , to its board of ...
    7-10-2013
  • Top 20 Venture Capital Firms
    ... Stemgent, Threshold Pharmaceutical, Tragara Pharmaceuticals, Trellis Bioscience, Vical Typical investment range: Between $12 million and $20 million over several rounds; ...
    12-17-2012
  • People in the News
    ... Mammen P. Mammen, Jr., M.D. , joined Vical as vp, clinical vaccines. Thomas Malley OvaScience named Thomas Malley to its board of directors. Currently, he is on the board of ...
    12-1-2012
  • DNA Immunization Platform Licensed for Antibody Production
    Vical is focused on the application of its plasmid-based DNA delivery technology for the ... production," explains Vijay B. Samant, Vical president and CEO. "This agreement ...
    9-13-2012
  • Viral Load Assay Employed for Phase III CMV Vaccine Trial
    ASP0113 is an investigational vaccine licensed by Astrellas from Vical. Under terms of the ... develop and commercialize TransVax from Vical in July 2011, for use in the prevention ...
    9-6-2012
  • PCR Techniques
    Biomedical; Rohit Kumar Mahajan, Ph.D. , associate director, assay development at Vical; Chris Meda , consultant and former president at Response Genetics; Taka Murakami , ...
    6-15-2012
  • Virginia Commonwealth Uni to Evaluate Prophylactic CMV Vaccination...
    DNA vaccines company Vical is collaborating with researchers at the Virginia Commonwealth ... The money will be used to carry out preclinical in vivo testing. Vical will produce the ...
    5-25-2010
  • H1N1 Boosts Development in Pharma Sector
    ... Its FluBlok seasonal influenza vaccine completed Phase III studies and is currently under review at the FDA. Vical develops vaccine and immunotherapy products based on its DNA ...
    12-1-2009
  • H1N1 Pandemic Is Here but Moderate in Severity
    A number of smaller developers also have the technology and manufacturing to assist the government, as does some larger drug companies like Crucell, NovaVax, and Vical. Last month ...
    6-15-2009
  • Oxygen Biotherapeutics Inks CRADA for Its PFC Oxygen Carrier
    for the treatment of DCS and AGE by the fiscal year 2012. ♦♦♦ Related News Vical Commissioned for $1.3M to Produce Dengue Vaccine and Adjuvant for NMRC's Evaluation ...
    5-14-2009
  • CORPORATE ROUNDTABLE ON HUMAN DNA VACCINES
    CORPORATE ROUNDTABLE ON HUMAN DNA VACCINES- with panelists Avtar Dhillon, M.D., Joseph Kim, Ph.D., Michael Egan, Ph.D., Jeffrey Ulmer, Ph.D., Alan King, Ph.D., and Robert Bernard 0 ...
    2-19-2009
  • Vical Pockets $1M Milestone from Merck & Co.
    Vical received a $1 million milestone payment from Merck & Co. based on Merck's planned ... Vijay B. Samant, Vical's president and CEO. Vical Pockets $1M Milestone from Merck & Co.
    12-1-2008
  • SurModics, Vical, and CombinatoRx Lay Off Staff as Part of Restructuri...
    Vical will reduce its staff by 29 employees, approximately 20% of its total workforce, and ... four more years, it reports. SurModics, Vical, and CombinatoRx Lay Off Staff as Part of ...
    11-21-2008
  • Vical Commissioned for $1.3M to Produce Dengue Vaccine and Adjuvant...
    Vical received a $1.3 million contract from the Naval Medical Research Center (NMRC) to ... (E) genes for for all four serotypes of dengue using Vaxfectin under a CRADA with Vical. ...
    11-6-2008

  • Journal Articles

  • Interleukin 2 Gene Therapy for Prostate Cancer: Phase I Clinical...
    Arie Belldegrun, Cho-Lea Tso, Amnon Zisman, John Naitoh, Jonathan Said, Allan J. Pantuck, Andreas Hinkel, Jean deKernion, Robert Figlin
    Human Gene Therapy and Part B: Methods
    A functional DNA-lipid complex encoding the interleukin 2 (IL-2) gene (Leuvectin; Vical, San Diego, CA) was administered intraprostatically into the hypoecogenic tumor lesion, ...

GEN Webinars

View »

GEN Web Briefs

View »

GEN Poll

More » Poll Results » Archive »

Top Paid Women in Biopharma

Do you think the women on our list of the 20 top paid women executives in biopharma are underpaid?

Suggest a Poll